tetano
Editor, Senior Moderator
Signal Transduct Target Ther
. 2025 Jan 17;10(1):30.
doi: 10.1038/s41392-025-02126-w. Real-world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study
Haiyu Wang[SUP] #[/SUP][SUP] 1 [/SUP], Guangying Cui[SUP] #[/SUP][SUP] 1 [/SUP], Ming Cheng[SUP] #[/SUP][SUP] 2 [/SUP], Tuerganaili Aji[SUP] #[/SUP][SUP] 3 [/SUP], Guotao Li[SUP] #[/SUP][SUP] 4 [/SUP], Xinjun Hu[SUP] 5 [/SUP], Guangming Li[SUP] 6 [/SUP], Shixi Zhang[SUP] 7 [/SUP], Yanyang Zhang[SUP] 8 [/SUP], Linqi Diao[SUP] 8 [/SUP], Pan Li[SUP] 1 [/SUP], Ling Wang[SUP] 9 [/SUP], Yiqiang Yuan[SUP] 9 [/SUP], Guowu Qian[SUP] 10 [/SUP], Ruiqing Zhang[SUP] 3 [/SUP], Xiaoli Jin[SUP] 4 [/SUP], Juan Wang[SUP] 6 [/SUP], Hong Luo[SUP] 11 [/SUP], Donghua Zhang[SUP] 12 [/SUP], Mingming Wang[SUP] 7 [/SUP], Silin Li[SUP] 13 [/SUP], Zhan Song[SUP] 10 [/SUP], Mengzhao Yang[SUP] 1 [/SUP], Guanyue Su[SUP] 1 [/SUP], Ranran Sun[SUP] 1 [/SUP], Junbiao Chang[SUP] 14 [/SUP], Zujiang Yu[SUP] 15 [/SUP], Zhigang Ren[SUP] 16 [/SUP]
Affiliations
Azvudine and nirmatrelvir-ritonavir (Paxlovid) were widely used to treat patients with COVID-19 in China during the Omicron wave. However, the efficacy and safety of azvudine versus Paxlovid are poorly established. This study included 40,876 hospitalized patients with COVID-19 from eleven hospitals in Henan and Xinjiang Provinces, China. Clinical outcomes were compared between the two drugs via Kaplan-Meier analysis and Cox regression models. Additionally, in vitro and in vivo experiments were used to evaluate the antitumor effects and safety of both drugs. Single-cell RNA sequencing was performed to elucidate the tumor immune landscape after azvudine treatment. After propensity score matching, 2404 azvudine and 1202 Paxlovid recipients from Henan Province were included. Cox regression revealed that azvudine was related to an 18% lower risk of all-cause death than Paxlovid (95% CI: 0.676-0.987), was not obviously different in composite disease progression. The robustness of the findings was verified by the Xinjiang cohort and three sensitivity analyses. Fewer adverse events were observed in the azvudine group. Subgroup analysis revealed that azvudine provided greater benefits for patients with malignant tumors, significantly reducing both all-cause death (hazard ratio
: 0.33, 95% CI: 0.20-0.54) and composite disease progression (HR: 0.54, 95% CI: 0.33-0.88). Furthermore, azvudine can suppress the growth of hepatocellular carcinoma (HCC) by regulating CD4[SUP]+[/SUP] T and CD8[SUP]+[/SUP] T cells in vivo. These findings suggest that azvudine therapy is not inferior to Paxlovid in hospitalized COVID-19 patients and has fewer adverse effects. Notably, azvudine may offer greater clinical benefit for patients with HCC.
. 2025 Jan 17;10(1):30.
doi: 10.1038/s41392-025-02126-w. Real-world effectiveness and safety of oral azvudine versus nirmatrelvir‒ritonavir (Paxlovid) in hospitalized patients with COVID-19: a multicenter, retrospective, cohort study
Haiyu Wang[SUP] #[/SUP][SUP] 1 [/SUP], Guangying Cui[SUP] #[/SUP][SUP] 1 [/SUP], Ming Cheng[SUP] #[/SUP][SUP] 2 [/SUP], Tuerganaili Aji[SUP] #[/SUP][SUP] 3 [/SUP], Guotao Li[SUP] #[/SUP][SUP] 4 [/SUP], Xinjun Hu[SUP] 5 [/SUP], Guangming Li[SUP] 6 [/SUP], Shixi Zhang[SUP] 7 [/SUP], Yanyang Zhang[SUP] 8 [/SUP], Linqi Diao[SUP] 8 [/SUP], Pan Li[SUP] 1 [/SUP], Ling Wang[SUP] 9 [/SUP], Yiqiang Yuan[SUP] 9 [/SUP], Guowu Qian[SUP] 10 [/SUP], Ruiqing Zhang[SUP] 3 [/SUP], Xiaoli Jin[SUP] 4 [/SUP], Juan Wang[SUP] 6 [/SUP], Hong Luo[SUP] 11 [/SUP], Donghua Zhang[SUP] 12 [/SUP], Mingming Wang[SUP] 7 [/SUP], Silin Li[SUP] 13 [/SUP], Zhan Song[SUP] 10 [/SUP], Mengzhao Yang[SUP] 1 [/SUP], Guanyue Su[SUP] 1 [/SUP], Ranran Sun[SUP] 1 [/SUP], Junbiao Chang[SUP] 14 [/SUP], Zujiang Yu[SUP] 15 [/SUP], Zhigang Ren[SUP] 16 [/SUP]
Affiliations
- PMID: 39819859
- PMCID: PMC11739574
- DOI: 10.1038/s41392-025-02126-w
Azvudine and nirmatrelvir-ritonavir (Paxlovid) were widely used to treat patients with COVID-19 in China during the Omicron wave. However, the efficacy and safety of azvudine versus Paxlovid are poorly established. This study included 40,876 hospitalized patients with COVID-19 from eleven hospitals in Henan and Xinjiang Provinces, China. Clinical outcomes were compared between the two drugs via Kaplan-Meier analysis and Cox regression models. Additionally, in vitro and in vivo experiments were used to evaluate the antitumor effects and safety of both drugs. Single-cell RNA sequencing was performed to elucidate the tumor immune landscape after azvudine treatment. After propensity score matching, 2404 azvudine and 1202 Paxlovid recipients from Henan Province were included. Cox regression revealed that azvudine was related to an 18% lower risk of all-cause death than Paxlovid (95% CI: 0.676-0.987), was not obviously different in composite disease progression. The robustness of the findings was verified by the Xinjiang cohort and three sensitivity analyses. Fewer adverse events were observed in the azvudine group. Subgroup analysis revealed that azvudine provided greater benefits for patients with malignant tumors, significantly reducing both all-cause death (hazard ratio
: 0.33, 95% CI: 0.20-0.54) and composite disease progression (HR: 0.54, 95% CI: 0.33-0.88). Furthermore, azvudine can suppress the growth of hepatocellular carcinoma (HCC) by regulating CD4[SUP]+[/SUP] T and CD8[SUP]+[/SUP] T cells in vivo. These findings suggest that azvudine therapy is not inferior to Paxlovid in hospitalized COVID-19 patients and has fewer adverse effects. Notably, azvudine may offer greater clinical benefit for patients with HCC.